chronic heart failure

Anti-Heart Failure Agent 1 is an orally available compound suitable for the treatment of heart failure without inducing vomiting, nausea, and restlessness.

Finerenone (BAY-948862) is a third-generation, selective, and orally available nonsteroidal mineralocorticoid receptor (MR) antagonist with IC50 of 18 nM for the treatment of chronic heart failure. Finerenone (BAY-948862) displays excellent selectivity versus glucocorticoid receptor (GR), androgen receptor (AR), and progesterone receptor (>500-fold).

Imazodan hydrochloride (CI-914 HCl) is a potent and selective type III phosphodiesterase inhibitor used in the treatment of chronic congestive heart failure.

Candoxatril (UK 79300) is an orally active neutral peptide endonuclease (NEP, EC 3.4.24.11) inhibitor that improves exercise capacity in patients with chronic heart failure undergoing angiotensin-converting enzyme inhibition.

Nolomirole HCl (CHF 1035) is a novel selective dopamine agonist with oral activity and inhibitory effects on norepinephrine release, which can be used to study mild chronic heart failure.

(±)-Prenalterol (H 80/62) is a new cardioselective positive inotropic compound that is an agonist of beta-2- and beta-1-adrenergic receptors and can be used to study chronic congestive heart failure.

Nebivolol hydrochloride (R 065824 hydrochloride) is a cardioselective ADRENERGIC BETA-1 RECEPTOR ANTAGONIST (beta-blocker) that functions as a VASODILATOR through the endothelial L-arginine/ NITRIC OXIDE system. It is used to manage HYPERTENSION and chronic HEART FAILURE in elderly patients.

AZD9977 is a novel, selective modulator of mineralocorticoid receptor .

TRPC3/6-IN-1 is a highly potent and selective inhibitor that specifically blocks the activity of the canonical transient receptor channels TRPC3 and TRPC6. It exhibits a significant blocking potency against the human isoforms hTRPC3 and hTRPC6, with IC50 values of 1260 nM and 500 nM, respectively. This compound, TRPC3/6-IN-1, is particularly valuable for conducting research on chronic models of heart failure [1].

Enalapril Maleate (MK-421 Maleate), an angiotensin-converting enzyme (ACE) inhibitor, is utilized in the treatment of hypertension, chronic heart failure , and diabetic nephropathy.

Omecamtiv mecarbil (CK-1827452) has been used in trials studying the treatment and basic science of Heart Failure, Echocardiogram, Pharmacokinetics, Chronic Heart Failure, and History of Chronic Heart Failure, among others.

Benzofurodil is cardiotonic used for the chronic treatment of congestive heart failure.

Perindopril (S-9490) is a long-acting ACE inhibitor effective for 24 hours, primarily utilized in the management of high blood pressure, heart failure, or stable coronary artery disease. Available as perindopril arginine (with trade names such as Coversyl and Coversum) or perindopril erbumine (known as Aceon), both formulations are regarded therapeutically equivalent, according to the Australian Government's Pharmaceutical Benefits Scheme—meaning they can be interchanged without clinical effect differences, though their dosing may vary due to distinct molecular weights. Notably, perindopril ranks among the most frequently prescribed ACE inhibitors, thanks to its extensive evidence base supporting its use in patients with hypertension, type 2 diabetes, coronary heart disease, and chronic heart failure. This review highlights perindopril's organoprotective benefits that extend beyond its capacity to lower blood pressure.

Azilsartan mepixetil is a potent angiotensin II receptor antagonist with enhanced efficacy and prolonged duration of action. It exhibits more prominent and sustained effects in lowering blood pressure and heart rate, while maintaining a high level of safety. Furthermore, Azilsartan mepixetil demonstrates optimal protective efficacy for cardiovascular and renal functions. Hence, it holds promise for the research and treatment of hypertension, chronic heart failure, and diabetic nephropathy.

Bucindolol (BMY 13105) is a novel and potent β1-adrenergic receptor blocker that mediates vasodilation and can be used to study chronic heart failure.

Imidapril (TA-6366 free base) is an orally active inhibitor of angiotensin-converting enzyme (ACE) and MMP-9. Imidapril inhibits the conversion of angiotensin I to angiotensin II, thereby reduces total peripheral resistance and systemic blood pressure. Imidapril has research value in hypertension, type 1 diabetic, nephropathy and chronic heart failure.

Finerenone-d5 is a deuterated compound of Finerenone. Finerenone has a CAS number of 1050477-31-0. Finerenone is a third-generation, selective, and orally available nonsteroidal mineralocorticoid receptor (MR) antagonist with IC50 of 18 nM for the treatment of chronic heart failure. Finerenone displays excellent selectivity versus glucocorticoid receptor (GR), androgen receptor (AR), and progesterone receptor (>500-fold). 

Imidapril hydrochloride (Tanapril) is an angiotensin-converting enzyme (ACE) inhibitor with IC50 of 2.6 nM, used for the treatment of hypertension.

Saterinone is a potent and selective phosphodiesterase III inhibitor and a potent antagonist of the vascular α-1-adrenoceptor. Saterinone has vasodilatory properties and can be used in the acute treatment of chronic heart failure. Saterinone inhibited crude cAMP phosphodiesterase (PDE) activity in guinea pig right ventricular homogenates The ic50 value is 2.3 × 10(-5) mol/l.

Azilsartan medoxomil potassium (QR-01019K), an angiotensin II receptor antagonist, exhibits a potent and sustained antihypertensive effect, along with a more pronounced and enduring reduction in heart rate, and a high safety profile. It shows promise for investigation in the management of hypertension, chronic heart failure, and diabetic nephropathy[1].

Efonidipine HCl (NZ-105) serves as both a T-type and L-type calcium channel blocker. This compound, distinct from other calcium channel blockers, notably increases N(6), 2'-O-dibutyryladenosine 3',5'-cyclic monophosphate (dbcAMP)-induced StAR mRNA and DHEA-S production in NCI-H295R adrenocortical carcinoma cells, actions reflective of adrenocorticotropic hormone. Efonidipine uniquely inhibits calcium channels by merging tonic and use-dependent blocking methods. Its inhibitory concentrations (IC50) for I(Ca(T)) and I(Ca(L)) are 0.35 micromol/l and 1.8 nmol/l, respectively. Clinically, efonidipine administered to hypertensive patients undergoing chronic hemodialysis (20-60 mg, twice daily) demonstrated comparable blood pressure control to amlodipine (2.5-7.5 mg, once daily) over a 12-week period without significantly altering pulse rate. Furthermore, efonidipine significantly improved left ventricular ejection fraction in heart failure models without affecting blood pressure, in addition to lowering the heart rate by about 10%.

Eplerenone (CGP 30083) is an aldosterone receptor antagonist and potassium-sparing diuretic used in the therapy of hypertension. Eplerenone therapy has been associated with transient elevations in serum aminotransferase levels, but has yet to be linked to cases of clinically apparent drug induced liver disease.

(R)-Finerenone-d5 is a deuterated compound of (R)-Finerenone. (R)-Finerenone has a CAS number of 1050477-30-9.

Rac-Finerenone, also known as (Rac)-BAY 94-8862, is the racemate derivative of Finerenone, a selective third-generation nonsteroidal mineralocorticoid receptor antagonist (MR) that is taken orally. With an IC50 value of 18 nM, Finerenone exhibits exceptional selectivity against the glucocorticoid receptor (GR), androgen receptor (AR), and progesterone receptor (>500-fold).